Eikon Therapeutics, Inc. EIKN
—
7.92
(0.37)
(4.46%)
as of 25 Sep
- Market cap
- $449.0M
- P/E
- 0.0×
Follow EIKN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (90.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (56.20%) | |
Free Cash Flow per Share |
0.00 | 0.00 | (13.55) | (8.22) | |
Free Cash Flow |
— | (586.19) | (456.65) | (444.98) | |
Capital Expenditures |
— | (175.62) | (91.08) | (68.97) | |
Piotroski F-Score |
— | — | — | 0.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 75.66% | (34.38%) | (37.67%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 1.07 | |
Depreciation/Fixed assets |
— | 0.44 | 0.30 | 0.31 | |
Capex/Depreciation |
— | (2.82) | (2.17) | (1.70) | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (10.85) | (6.94) | |
Capex per Share |
0.00 | 0.00 | (2.70) | (1.27) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates